Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8157MR)

This product GTTS-WQ8157MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF1A gene. The antibody can be applied in Dry eye (DE) syndrome research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001065.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7132
UniProt ID P19438.1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8157MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10251MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LFB-R603
GTTS-WQ428MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 3C23K
GTTS-WQ14444MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ9668MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ4555MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ6604MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DC-1728001
GTTS-WQ9676MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ7298MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW